To our best knowledge, this is the first study to unequivocally identify the NEMO/IKKβ complex as the anti-tumor target of SHK using a combination strategy of molecular pharmacological phenotyping, proteomics, and bioinformatics analysis. This evidence concerns the gene IKBKB and neoplasm.